Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GPX4 | P36969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436752 | 0.81 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL25985564 | 0.80 | NPSR1 (0.48) | NPSR1KMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL9585593 | 0.78 | ALDH1A1 (0.50) | NPSR1KMT2AALDH1A1MEN1USP2 | |
| SCHEMBL22609288 | 0.78 | GRIA1 (0.46) | KMT2AALDH1A1MEN1GPX4 | |
| SCHEMBL15248892 | 0.78 | BRD4 (0.41) | KMT2AALDH1A1ALOX15HSD17B10POLB | |
| SCHEMBL31226160 | 0.77 | NPSR1 (0.45) | NPSR1KMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL19893057 | 0.77 | NPSR1 (0.45) | NPSR1KMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL31226129 | 0.77 | ALDH1A1 (0.45) | NPSR1KMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL5431807 | 0.77 | NPSR1 (0.45) | NPSR1KMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL4777369 | 0.76 | ALDH1A1 (0.51) | NPSR1KMT2AALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| CN-119569706-A | Therapeutic compounds | 希四克斯探索有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-112996785-B | Therapeutic compounds | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-12098148-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2024-09-24 | — | — | US | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| CN-112996785-A | Therapeutic compounds | 希四克斯探索有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3731840-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | Orfan Biotech Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | NPSR1 2304/4885KMT2A 3198/4885ALDH1A1 307/4885 |
| US-12098148-B2 | Therapeutic compounds | NFE2L2, KEAP1, NQO1 | NPSR1 2304/4885KMT2A 3198/4885ALDH1A1 307/4885 |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | NPSR1 2304/4885KMT2A 3198/4885ALDH1A1 307/4885 |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | NPSR1 3687/4885KMT2A 3407/4885ALDH1A1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.